<?xml version="1.0" encoding="UTF-8"?>
<p>The TRICOLORE trial compares bevacizumab + mFOLFOX6 or CapeOX with bevacizumab + IRI + S‐1. Representative prospective clinical trials comparing fluoropyrimidines (FIRIS, SOFT, NO16966, and AXEPT) in mCRC have shown that the PFS rates of 5‐FU, capecitabine, and S‐1 are comparable.
 <xref rid="cas14841-bib-0022" ref-type="ref">
  <sup>22</sup>
 </xref>, 
 <xref rid="cas14841-bib-0023" ref-type="ref">
  <sup>23</sup>
 </xref>, 
 <xref rid="cas14841-bib-0024" ref-type="ref">
  <sup>24</sup>
 </xref>, 
 <xref rid="cas14841-bib-0025" ref-type="ref">
  <sup>25</sup>
 </xref> Therefore, we believe that our findings can be used to compare the clinical outcomes of OX‐based and IRI‐based therapies.
</p>
